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Purpose of the study
We aimed to investigate which measures of prior viral sup-
pression predicted uncontrolled viremia in patients on
cART who started >1 antiretrovirals (ARV) after 1/1/2003.
Methods
1,807 EuroSIDA patients on cART that started any ARV
after January 1, 2003 were included. Baseline was defined
as the date of starting a new ARV after January 1, 2003.
Poisson regression, adjusted for appropriate confounding
variables, was used to identify measures of viral suppres-
sion before baseline which predicted risk of uncontrolled
viremia (viral load [VL] >500 copies/ml at least 6 months
after baseline) after starting a new ARV. Measures of viral
suppression before baseline were number of rebounds
(VL >500 copies/ml), size of rebounds, time since last
rebound, highest ever rebound, and the total time sup-
pressed and percentage of time suppressed while on cART
prior to baseline.
Summary of results
At baseline patients had been on cART a median of 6.2
years (IQR 4.7–7.3), and had been exposed to a median
of seven ARVs (IQR 5–9). The most common reasons for
starting a new ARV was patient/physician choice (32%)
and toxicities (31%); 66% were suppressed at baseline.
530 patients experienced uncontrolled viremia (400
whilst on cART) after starting a new ARV. The incidence of
uncontrolled viremia was 13.7/100 PYFU (95%
CI:12.5–14.9). Figure 1 show the crude incidence of
uncontrolled viremia after stratification by the number of
rebounds and the proportion of time fully suppressed
while on cART prior to baseline. In adjusted models, the
rate of uncontrolled viremia was lower in those with fewer
viral rebounds before baseline (IRR per additional prior
rebound = 1.12 (95% CI: 1.04–1.20), and with increasing
time fully suppressed on cART prior to baseline (IRR per
additional 10% suppressed = 0.86 (0.83–0.90). Higher
rebound values and less time since last rebound also
increased the risk of uncontrolled viremia but were not
significant after adjustment for time suppressed and
number of previous rebounds. The results were consistent
between patients suppressed and unsuppressed at base-
line.
Conclusion
The number of previous rebounds and the percentage of
time suppressed whilst on cART were both strong predic-
tors of future uncontrolled viremia after starting a new
ARV. Hence, the history of patterns of viral response to
cART regimens should be an integrated component in
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deciding monitoring strategies and adherence counseling
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